Biomarkers of aHSCT

Multiple Sclerosis, Relapsing-Remitting Clinical Trial

— BIO-MS  

Official title:

Identifying Immune Biomarkers of Disease and Disease Control in Autoimmune Neurological Disease Using Autologous Haematopoietic Stem Cell Transplantation

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06195800
• Other study ID #: STH22343
• Status: Recruiting
• Start date: August 9, 2023
• Est. completion date: August 9, 2026

Study information

• Verified date: January 2024
• Source: Sheffield Teaching Hospitals NHS Foundation Trust
• Contact: Gavin Brittain, MBBS, MRCP
• Phone: +44114 271 1900
• Email: gavin.brittain[@]sheffield.ac.uk
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The underlying disease mechanisms which occur in patients with immune mediation neurological diseases, such as Multiple Sclerosis (MS), are incompletely understood. For such patients, autologous haematopoietic stem cell transplantation (aHSCT) has been increasingly used as a highly successful one-off treatment for some patients. This treatment aims to delete the faulty immune system with a course of chemotherapy and then 'reboot' the immune system using a patients' own stem cells (a cell with the unique ability of being a building block to create many different cells in the body) to stop further damage. Over the last 20 years more than 1800 patients with MS have been treated in Europe with high levels of success. It may be more successful than disease modifying treatment but unfortunately, a small portion of people do not respond to this treatment optimally and continue to accumulate disability. There is a risk of side effects, restricted largely to the time of treatment, which necessitates the need to ensure appropriate patients are treated. Whilst aHSCT is a very effective therapy, it is still in its early phase of development, is not in widespread use, and there is incomplete knowledge regarding how it works and importantly, why it does not work in some patients, and how to monitor response to treatment.

Unfortunately, there is no way of detecting which patients will, and will not, benefit from the different treatments available or a way of monitoring the immune system to ensure further treatment is provided before irreversible damage occurs.

This study will investigate the immune system which is found in the fluid surrounding the brain and spinal cord, blood and stool of patients undergoing aHSCT and compare it to those receiving disease modifying treatment. This study will therefore further the understanding of biomarkers of aHSCT to develop an awareness of how it can be refined, may improve monitoring of patients following treatment and permit the development of markers which can predict potential treatment success or failure before patients are exposed to the risks.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 15
• Est. completion date: August 9, 2026
• Est. primary completion date: August 9, 2026
• Accepts healthy volunteers: No
• Gender: All
• Age group: 16 Years and older

Eligibility

Inclusion Criteria:

1. Diagnosis of a immune mediated neurological disease according to disease specific criteria (active treatment arm) or diagnosis of relapsing remitting multiple sclerosis (control arm).

2. Treatment with autologous haematopoetic stem cell transplantation (active treatment arm) or high efficacy disease modifying treatment (control arm).

3. Willing to provide biological samples for analysis and undergo clinical assessments for the duration of follow up.

4. Able to understand English and provide informed consent.

Exclusion Criteria:

1. Inability to provide informed consent.

Related Conditions & MeSH terms

• Multiple Sclerosis
• Multiple Sclerosis, Relapsing-Remitting
• Sclerosis

Locations

Country	Name	City	State
United Kingdom	Sheffield Teaching Hospitals NHS Foundation Trust	Sheffield	England

Sponsors (4)

Lead Sponsor	Collaborator
Sheffield Teaching Hospitals NHS Foundation Trust	Nottingham Trent University, Sheffield Hospitals Charity, University of Sheffield

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Quantitatively and qualitatively characterise the immune profile of the stem cells, blood, cerebrospinal fluid (CSF) and the microbiome pre and post treatment.	Phenotype profiling of stem cells, cells in blood and CSF using multi-parameter flow cytometry.; Profile the gut microbiome using 16S rRNA sequencing and flow cytometric analysis.	24 months
Primary	Perform single cell RNA sequencing (scRNA-Seq) on paired CSF and blood pre and post treatment.	Profiling of T cell receptor and B cell receptor repertoire diversity and clonality	24 months
Secondary	Characterisation of the regeneration of mucosal cell immunity and the reconstitution of pathogen specific immunity following aHSCT by scRNA-Seq on nasopharyngeal swabs and mucosal strips.	Assess immune response in treated patients post vaccination.	24 months
Secondary	Evaluate immunological disease response and the duration of response to aHSCT according to expanded disability status scale score (EDSS)	EDSS to be observed longitudinally following treatment.	24 months
Secondary	Evaluate immunological disease response and the duration of response to aHSCT according to low contrast visual acuity (LCLA)	LCLA to be observed longitudinally following treatment.	24 months
Secondary	Evaluate immunological disease response and the duration of response to aHSCT according to multiple sclerosis functional composite score (MSFC)	MSFC to be observed longitudinally following treatment.	24 months
Secondary	Evaluate immunological disease response and the duration of response to aHSCT according to short form 36 (SF-36)	SF-36 to be observed longitudinally following treatment.	24 months
Secondary	Evaluate immunological disease response and the duration of response to aHSCT according to symbol digit modality test (SDMT)	SDMT to be observed longitudinally following treatment.	24 months
Secondary	Evaluate immunological disease response and the duration of response to aHSCT according to Karnofsky performance status	Karnofsky performance status to be observed longitudinally following treatment.	24 months